Promising New Evidence Supports Ketogenic Therapy for Anorexia Nervosa Treatment

Why It Matters

The study provides proof‑of‑concept that targeting brain metabolism can enhance recovery in a disorder with high relapse rates, potentially reshaping standard eating‑disorder treatment models.

Key Takeaways

• 22 adults completed 14‑week ketogenic trial; 82% retention.
• 72% reached recovered scores on EDE‑Q and EDI‑3 assessments.
• All participants showed depression score normalization; 72% normal BDI.
• No weight loss observed; BMI remained stable throughout study.
• Study paves way for larger trials integrating metabolic psychiatry in eating‑disorder care.

Pulse Analysis

The emerging view that eating disorders have a neurobiological component has opened the door to metabolic interventions. Ketogenic therapy, long used to control seizures by shifting brain fuel from glucose to ketones, is now being repurposed for psychiatric conditions. Researchers at UC San Diego leveraged this mechanism, hypothesizing that stabilizing neuronal energy metabolism could correct the dysregulated appetite and mood circuits seen in anorexia nervosa. By framing the diet as a precision‑medicine tool rather than a restrictive regimen, the study aligns nutritional science with modern psychiatry.

The 14‑week pilot enrolled 22 adults with weight‑normalized or mildly underweight anorexia and achieved an 82 % completion rate, demonstrating feasibility under close medical supervision. Seventy‑two percent of completers scored in the recovered range on standard eating‑disorder questionnaires, while the same proportion attained normal Beck Depression Inventory scores, indicating concurrent mood improvement. Importantly, participants maintained stable body‑mass indices, quelling concerns that a high‑fat, low‑carb diet would trigger further weight loss. These outcomes suggest that metabolic correction can produce both physiological stability and psychological relief, challenging the dominance of purely psychotherapeutic models.

Building on this proof‑of‑concept, the investigators have launched an extension trial that includes bulimia nervosa patients and plan a multicenter randomized study. If larger cohorts replicate the findings, metabolic psychiatry could become a reimbursable component of eating‑disorder treatment packages, attracting investment from biotech firms and philanthropic foundations alike. Clinicians would gain a new evidence‑based tool to address relapse risk, while insurers might see reduced long‑term costs associated with chronic care. Ultimately, the research signals a shift toward biologically targeted therapies that could reshape standards of care for some of psychiatry’s most treatment‑resistant illnesses.